Table 3.
Univariable and multivariable logistic regression analysis for patients who started and did not start with immunosuppressive therapy as a result from the care pathway
| Start N=49 |
Not started N=177 |
Univariable OR (95% CI) | p Value | Multivariable OR (95% CI) | p Value | |
|---|---|---|---|---|---|---|
| Sociodemographics | ||||||
| Age, years, mean (SD) | 48 (15) | 56 (14) | 0.96 (0.94 to 0.98) | <0.001 | 0.94 (0.91 to 0.98) | 0.005 |
| Female, N (%) | 38 (78) | 140 (86) | 1.76 (0.79 to 3.93) | 0.167 | ||
| Disease duration, years, median (IQR) | 1 (0–4) | 4 (1–12) | 0.93 (0.88 to 0.98) | 0.012 | ||
| Onset of RP, years, median (IQR) | 6 (2–16) | 13 (6–21) | 0.96 (0.93 to 0.99) | 0.020 | ||
| Onset of non-RP, years, median (IQR) | 3 (1–5) | 7 (3–13) | 0.94 (0.89 to 0.99) | 0.016 | ||
| Disease characteristics, N (%) | ||||||
| DcSSc | 26 (53) | 33 (56) | 4.45 (2.26 to 8.78) | <0.001 | 1.33 (0.35 to 5.05) | 0.676 |
| Digital ulcers | 11 (22) | 49 (30) | 0.66 (0.31 to 1.40) | 0.281 | ||
| Telangiectasia | 20 (41) | 107 (66) | 0.35 (0.18 to 0.68) | 0.002 | 0.46 (0.16 to 1.30) | 0.155 |
| Synovitis | 8 (16) | 15 (9) | 1.93 (0.76 to 4.86) | 0.165 | ||
| Friction rubs | 4 (8) | 4 (3) | 3.53 (0.85 to 14.69) | 0.083 | ||
| Proximal muscular weakness | 8 (16) | 6 (4) | 5.07 (1.67 to 15.44) | 0.004 | 5.06(0.93 to 27.68) | 0.061 |
| Pulmonary crackles | 21 (44) | 36 (22) | 2.72 (1.38 to 5.37) | 0.004 | 2.44 (0.74 to 8.02) | 0.142 |
| mRSS, median (IQR) | 5 (2–20) | 2 (0–5) | 1.13 (1.07 to 1.18) | <0.001 | 1.09 (1.00 to 1.01) | 0.042 |
| Anti-Scl-70 antibody | 18 (37) | 28 (17) | 4.07 (1.88 to 8.82) | <0.001 | ||
| Anticentromere antibody | 4 (8) | 72 (44) | 0.11 (0.04 to 0.33) | <0.001 | ||
| Diagnostic investigations | ||||||
| ESR, mm, median (IQR) | 19 (11–41) | 14 (6–28) | 1.02 (1.00 to 1.03) | 0.033 | ||
| CRP, mg/dL, median (IQR) | 3 (3–7) | 3 (3–4) | 1.04 (1.01 to 1.07) | 0.020 | ||
| CPK, mg/dL, median (IQR) | 95 (54–174) | 85 (61–114) | 1.01 (1.00 to 1.01) | 0.009 | 1.01 (1.000 to 1.01) | 0.039 |
| Vital capacity % of predicted, mean (SD) | 86 (19) | 98.6 (21) | 0.97 (0.95 to 0.99) | <0.001 | ||
| NSIP according HRCT, N (%) | 27 (55) | 36 (22) | 4.13 (2.10 to 8.10) | <0.001 | 4.89 (1.561 to 15.30) | 0.006 |
| CPET; maximum VO2% of predicted, mean (SD) | 79 (20) | 91 (26) | 0.98 (0.97 to 0.99) | 0.006 | ||
CPET, cardiopulmonary exercise test; CPK, creatine phosphokinase; CRP, C reactive protein; DcSSc, diffuse cutaneous SSc; DU, digital ulcers; ESR, erythrocyte sedimentation rate; MRSS, modified Rodnan Skin Score; NSIP, non-specific interstitial pneumonia; VO2 max, maximum volume oxygen.